HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis)
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Adverse reactions
- Sponsors AbbVie
- 28 Dec 2016 Status changed from not yet recruiting to recruiting.
- 08 Nov 2016 Planned initiation date changed from 1 Sep 2016 to 1 Jan 2017.
- 30 Sep 2016 New trial record